A Phase 1b Study of SAR65098 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
ID Number 16-0568Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to test the safety of SAR650984 with carfilzomib at different dose levels. We want to find out what effects, good and/or bad, the combination has on you and your myeloma. SAR650984 is an antibody directed against CD38, a receptor antigen. SAR650984 may stop the growth of some blood cancers SAR650984 is an investigational drug, which means it has not been approved for use by the U.S. Food and Drug Administration (FDA).
Recruiting Patients: Yes